NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$24.42
+0.48 (+2.01%)
Close of Nov 06, 2026 · end-of-day data
PRVA 8-K filings, explained
Every material Form 8-K Privia Health Group has filed with the SEC since May 09, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Privia Health reported third-quarter 2026 revenue of $657.0 million, up 13.2% from a year earlier, and net income attributable to the company of $13.5 million, up from $6.9 million. The company raised its full-year 2026 guidance, including Adjusted EBITDA of $154 million to $157 million, up from the initial range of $145 million to $155 million. It also agreed to acquire American Choice Healthcare MSSP for approximately $36 million in cash and will exit its Montana partnership effective January 2027.
Q3 2026 total revenue was $657.0 million, up from $580.4 million; diluted net income per share was $0.10, up from $0.05.
Updated FY 2026 Adjusted EBITDA guidance is $154 million to $157 million, versus initial guidance of $145 million to $155 million given February 27, 2026.
Updated FY 2026 GAAP revenue guidance is $2,500 million to $2,550 million, versus initial guidance of $2,350 million to $2,450 million.
Cash and cash equivalents were $446.3 million at September 30, 2026, with no debt; the company expects at least $520 million in year-end cash including the acquisition.
Privia Health Group's board elected Opella Ernest, M.D., a former HCSC executive, as a Class III director effective September 1, 2026, and named her to the Compliance Committee. The change adds a director to the board and carries a $200,000 grant-date value equity award, but the filing does not describe any financial results or operational impact.
Dr. Ernest was elected by the board on August 12, 2026, effective September 1, 2026.
She was appointed to the Compliance Committee effective September 1, 2026.
Non-employee director pay includes an annual cash retainer and restricted stock units with a $200,000 grant-date fair market value.
Dr. Ernest is currently President, HCSC Markets at Health Care Service Corporation, a role held since 2023.
Privia Health Group reported second-quarter 2026 revenue of $632.6 million, up 21.4% from a year earlier, and net income attributable to the company of $9.0 million, up from $2.7 million. The company also raised its full-year 2026 guidance for all key financial metrics, including Adjusted EBITDA of $145 million to $155 million, which indicates improved profitability expectations for shareholders.
Q2 2026 revenue was $632.6 million, up 21.4% from $521.2 million in Q2 2025.
Q2 2026 net income attributable to Privia was $9.0 million, or $0.07 per share, versus $2.7 million, or $0.02 per share, a year earlier.
Q2 2026 Adjusted EBITDA was $37.4 million, up 29.1% from $29.0 million.
Updated full-year 2026 guidance includes Adjusted EBITDA of $145 million to $155 million and GAAP revenue of $2.35 billion to $2.45 billion.
Shawn Morris resigned from Privia Health Group's Board of Directors and its Compliance Committee, effective immediately, on July 6, 2026. The company said the resignation was not due to any disagreement over its operations, policies, or practices.
Resignation effective July 6, 2026, with immediate effect
Morris left the Board and the Compliance Committee of the Board
Company states no disagreement on operations, policies, or practices
Privia Health reported first-quarter 2026 revenue of $603.8 million, up 25.8% from a year earlier, and adjusted EBITDA of $36.7 million, up 36.3%. GAAP net income attributable to the company fell to $3.1 million from $4.2 million, while non-GAAP adjusted net income rose 22.3% to $24.3 million. The company kept most full-year 2026 guidance unchanged and raised its attributed lives range.
Total revenue was $603.8 million versus $480.1 million, up 25.8%.
Net income attributable to Privia Health was $3.1 million, or $0.02 per share, versus $4.2 million, or $0.03 per share, a year earlier.
Non-GAAP adjusted net income per diluted share was $0.19 versus $0.16; adjusted EBITDA was $36.7 million versus $26.9 million.
Full-year 2026 guidance for GAAP revenue ($2,350 million to $2,450 million) and adjusted EBITDA ($145 million to $155 million) was unchanged; attributed lives guidance was raised to 1,600,000 to 1,625,000 from 1,550,000 to 1,600,000.
Privia Health reported fourth-quarter and full-year 2025 results, with Q4 revenue of $541.2 million, up 17.4% from a year earlier, and full-year revenue of $2.12 billion, up 22.3%. The company also issued 2026 guidance calling for GAAP revenue of $2.35 billion to $2.45 billion and Adjusted EBITDA of $145 million to $155 million, compared with $125.5 million in 2025.
Q4 2025 net income attributable to Privia was $9.2 million, versus $4.4 million in Q4 2024; full-year net income was $22.9 million, up 59.3%.
Full-year 2025 Adjusted EBITDA was $125.5 million, up 38.8%, and operating cash flow was $163.4 million, up 49.5%.
Year-end 2025 cash was $479.7 million with no debt.
2026 guidance: GAAP revenue $2,350 million to $2,450 million; Adjusted EBITDA $145 million to $155 million; about $600 million expected year-end cash.
Privia Health reported third-quarter 2025 revenue of $580.4 million, up 32.5% from a year earlier, and net income attributable to the company of $6.9 million, up from $3.5 million. The company raised its full-year 2025 outlook, including GAAP revenue guidance of $2.05 billion to $2.1 billion and Adjusted EBITDA guidance of $118 million to $121 million, both above prior ranges.
Q3 2025 total revenue was $580.4 million, up 32.5% from $437.9 million in Q3 2024.
Net income attributable to Privia Health Group was $6.9 million, or $0.05 per diluted share, versus $3.5 million, or $0.03, a year earlier.
Updated FY2025 guidance: GAAP revenue $2.05 billion to $2.1 billion (previously $1.8 billion to $1.9 billion); Adjusted EBITDA $118 million to $121 million (previously $105 million to $110 million).
Pending acquisition of Evolent Health's ACO business for $100 million in cash plus up to $13 million more, expected to close in Q4 2025; the company had $441.4 million in cash and no debt at September 30, 2025.
Privia Health reported second-quarter 2025 total revenue of $521.2 million, up 23.4% from a year earlier, and raised its full-year 2025 guidance. GAAP net income attributable to Privia shareholders fell to $2.7 million from $3.5 million, while non-GAAP adjusted net income per diluted share rose to $0.24 from $0.19. The results are preliminary and unaudited until the company's Form 10-Q is filed.
Q2 2025 total revenue was $521.2 million, versus $422.3 million in Q2 2024, up 23.4%.
Q2 net income attributable to Privia shareholders was $2.7 million, or $0.02 per diluted share, versus $3.5 million, or $0.03, a year earlier.
Q2 Adjusted EBITDA was $29.0 million, up 31.6% from $22.0 million.
Updated FY 2025 guidance includes GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million, both above the high end of the prior range.
Privia Health Group expanded its board from nine to ten directors and elected Lance Berberian as a Class III director effective July 15, 2025, with a seat on the Audit Committee. The former Labcorp technology chief brings IT, cybersecurity and digital transformation experience to the board, according to the filing.
Board size increased from nine to ten directors; Berberian elected effective July 15, 2025
Berberian appointed to the Audit Committee effective July 15, 2025
Director pay includes an annual cash retainer and restricted stock units with a grant date fair value of $200,000
Berberian served as EVP and Chief Information and Technology Officer at Labcorp from 2014 to October 2024
Privia Health reported first-quarter 2025 revenue of $480.1 million, up 15.6% from a year earlier, and net income attributable to the company of $4.2 million, up from $3.0 million. The company raised its full-year 2025 outlook to the mid-to-high end of most guidance ranges, with attributed lives unchanged, and said it entered Arizona through a $95 million cash acquisition of Integrated Medical Services.
Q1 2025 total revenue was $480.1 million, up from $415.2 million; operating income was $5.2 million, compared with $0.8 million
Net income per share was $0.03, compared with $0.02 in Q1 2024; non-GAAP adjusted net income per share was $0.22, compared with $0.18
Full-year 2025 GAAP revenue guidance is $1.8 billion to $1.9 billion, with most metrics raised to the mid-to-high end of ranges; attributed lives guidance is unchanged
On April 9, 2025, the company entered Arizona with the $95 million cash acquisition of Integrated Medical Services, which is expected to be profitable starting in Q4 2025
Privia Health amended the employment agreement of Parth Mehrotra on March 3, 2025, through a fifth amendment filed as Exhibit 10.1. The amendment sets a $650,000 annual base salary effective March 24, 2025, an annual bonus of up to 125% of base salary, and a long-term incentive target value of $8 million, all starting with the 2025 performance year.
Base salary set at $650,000 annually, effective March 24, 2025
Annual performance bonus eligibility of up to 125% of base salary, starting with the 2025 performance year
Long-term incentive award target value of $8,000,000, starting with the award to be made in 2025
Amendment dated March 3, 2025, attached as Exhibit 10.1
Privia Health reported fourth-quarter 2024 revenue of $460.9 million, up 4.6%, and full-year revenue of $1.74 billion, up 4.7%. Full-year net income attributable to the company fell 37.7% to $14.4 million, while non-GAAP adjusted net income rose 19.8%, and the company gave 2025 guidance for GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million.
Q4 2024 net income attributable to Privia was $4.4 million, up from $2.8 million; diluted EPS was $0.03 versus $0.02
Full-year 2024 diluted EPS was $0.11 versus $0.19 in 2023, a 42.1% decline; non-GAAP adjusted diluted EPS rose 21.9% to $0.78
Full-year 2024 Adjusted EBITDA was $90.5 million, up 25.2%; year-end cash was $491.1 million with no debt
2025 guidance: GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million; guidance assumes no new business development activity
Privia Health reported third-quarter 2024 results on November 7, 2024, with revenue up 4.9% to $437.9 million and adjusted EBITDA up 25.8% to $23.6 million. GAAP net income fell 37.4% to $3.5 million, and GAAP diluted EPS fell to $0.03 from $0.05. The company raised its full-year 2024 guidance, with all listed metrics now at or above the high end of prior ranges.
Q3 2024 total revenue was $437.9 million, up 4.9% from $417.3 million; GAAP net income was $3.5 million versus $5.6 million a year earlier.
Adjusted EBITDA was $23.6 million, up 25.8%; non-GAAP adjusted net income per diluted share was $0.20 versus $0.17.
Full-year 2024 adjusted EBITDA guidance was raised to $85 million to $90 million, at the high end of the prior range.
Cash and cash equivalents were $422.0 million at September 30, 2024, with no debt.
Privia Health reported second-quarter 2024 results on August 8, 2024, with total revenue of $422.3 million, up 2.2% from a year earlier, while net income attributable to the company fell to $3.5 million from $7.3 million and diluted EPS fell to $0.03 from $0.06. The company also raised its full-year 2024 guidance to the mid-to-high end of its ranges for all metrics, including GAAP revenue of $1,600 million to $1,675 million, so shareholders get higher revenue expectations alongside lower GAAP earnings this quarter.
Q2 2024 total revenue $422.3 million, up 2.2% from $413.4 million; operating income $5.1 million, down 27.0%
Net income attributable to Privia Health $3.5 million, or $0.03 per share, versus $7.3 million, or $0.06, a year earlier
Adjusted EBITDA $22.0 million, up 14.0%; cash and cash equivalents $387.4 million and no debt as of the quarter
FY 2024 guidance raised to mid-to-high end; GAAP revenue guidance $1,600 million to $1,675 million, Adjusted EBITDA $85 million to $90 million
Privia Health Group disclosed that director Bill Sullivan resigned from its Board of Directors and the Board's Audit Committee effective immediately, on July 1, 2024. The company said the resignation was not due to any disagreement on the company's operations, policies, or practices.
Bill Sullivan resigned on July 1, 2024, effective immediately
He left both the Board of Directors and the Audit Committee
The filing states no disagreement with the company on operations, policies, or practices
Privia Health reported first quarter 2024 revenue of $415.2 million, up 7.5% from a year earlier, and reiterated its full-year 2024 guidance. GAAP net income fell to $3.0 million from $7.3 million and operating income fell to $0.8 million from $6.7 million, while non-GAAP adjusted EBITDA rose 18.1% to $19.9 million. Stock-based compensation was $11.9 million, up from $5.4 million, and the company did not change its outlook.
Total revenue was $415.2 million versus $386.3 million in Q1 2023, up 7.5%
Operating income was $0.8 million versus $6.7 million; net income was $3.0 million versus $7.3 million
Non-GAAP adjusted net income rose 16.6% to $22.5 million; adjusted EBITDA rose 18.1% to $19.9 million
Full-year 2024 guidance was reiterated, including GAAP revenue of $1,600 million to $1,675 million and adjusted EBITDA of $85 million to $90 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Privia Health Group filing is on SEC EDGAR ↗. 8-K briefs of other companies →